• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular pathogenesis of Waldenstrom's macroglobulinemia.华氏巨球蛋白血症的分子发病机制
Haematologica. 2012 Sep;97(9):1281-90. doi: 10.3324/haematol.2012.068478. Epub 2012 Jul 6.
2
Genetic factors and pathogenesis of Waldenström's macroglobulinemia.瓦尔登斯特伦巨球蛋白血症的遗传因素与发病机制。
Curr Oncol Rep. 2013 Oct;15(5):450-6. doi: 10.1007/s11912-013-0331-7.
3
Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.支持诊断和决定治疗骨髓外华氏巨球蛋白血症的胸腔液 MYD88 L265P 突变:一例报告。
J Med Case Rep. 2020 Jul 13;14(1):98. doi: 10.1186/s13256-020-02404-x.
4
Novel agents in the treatment of Waldenström's macroglobulinemia.治疗华氏巨球蛋白血症的新型药物
Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S199-206. doi: 10.3816/clm.2007.s.023.
5
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.瓦尔登斯特伦巨球蛋白血症中的 MYD88 L265P 体细胞突变。
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
6
Lymphoplasmacytic lymphoma with IgA paraproteinemia mimicking Waldenstrom's Macroglobulinemia.伴有IgA副蛋白血症的淋巴浆细胞淋巴瘤,酷似华氏巨球蛋白血症。
Indian J Pathol Microbiol. 2004 Oct;47(4):515-7.
7
Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis.微小 RNA 在华氏巨球蛋白血症发病机制中的关键作用。
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):109-11. doi: 10.3816/CLML.2011.n.022.
8
Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.意义未明的单克隆丙种球蛋白病和华氏巨球蛋白血症。
Best Pract Res Clin Haematol. 2016 Jun;29(2):187-193. doi: 10.1016/j.beha.2016.08.015. Epub 2016 Sep 4.
9
Bilateral ocular involvement as a presentation of Waldenström's macroglobulinemia.双侧眼部受累作为华氏巨球蛋白血症的表现。
Med Oncol. 2011 Dec;28(4):1624-5. doi: 10.1007/s12032-010-9648-3. Epub 2010 Aug 10.
10
IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.华氏巨球蛋白血症中的 IgA 和 IgG 低丙种球蛋白血症。
Haematologica. 2010 Mar;95(3):470-5. doi: 10.3324/haematol.2009.010348. Epub 2009 Nov 10.

引用本文的文献

1
Rare presentation of double-clonal Waldenström macroglobulinemia with pulmonary embolism: A case report.伴有肺栓塞的双克隆性华氏巨球蛋白血症罕见病例报告
Open Life Sci. 2023 Jun 14;18(1):20220619. doi: 10.1515/biol-2022-0619. eCollection 2023.
2
Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation.华氏巨球蛋白血症中的炎症与6号染色体长臂缺失及开始治疗的必要性相关。
Haematologica. 2022 Nov 1;107(11):2720-2724. doi: 10.3324/haematol.2022.281053.
3
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.华氏巨球蛋白血症和IgM单克隆丙种球蛋白病中的核酸生物标志物:当前见解与临床相关性
Diagnostics (Basel). 2022 Apr 12;12(4):969. doi: 10.3390/diagnostics12040969.
4
Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma.包括淋巴浆细胞淋巴瘤在内的肿瘤前体细胞突变。
Sci Adv. 2022 Jan 21;8(3):eabl4644. doi: 10.1126/sciadv.abl4644. Epub 2022 Jan 19.
5
Primary Isolated Lymphoplasmacytic Lymphoma (LPL) of the Stomach: A Case Report.胃原发性孤立性淋巴浆细胞淋巴瘤(LPL):一例报告。
Am J Case Rep. 2020 Jul 20;21:e921840. doi: 10.12659/AJCR.921840.
6
Waldenström macroglobulinemia: biology, genetics, and therapy.华氏巨球蛋白血症:生物学、遗传学与治疗
Blood Lymphat Cancer. 2016 Jul 26;6:49-58. doi: 10.2147/BLCTT.S84157. eCollection 2016.
7
Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.瓦尔登斯特伦巨球蛋白血症患者循环外泌体 miRNA 的分析。
PLoS One. 2018 Oct 4;13(10):e0204589. doi: 10.1371/journal.pone.0204589. eCollection 2018.
8
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.MYD88 突变性淋巴浆细胞淋巴瘤与 MYD88 突变性慢性淋巴细胞白血病的遗传学特征比较。
Leukemia. 2017 Jun;31(6):1355-1362. doi: 10.1038/leu.2016.330. Epub 2016 Nov 14.
9
[Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma].[非IgM型淋巴浆细胞淋巴瘤的临床与生物学特征]
Zhonghua Xue Ye Xue Za Zhi. 2015 Jun;36(6):493-6. doi: 10.3760/cma.j.issn.0253-2727.2015.06.010.
10
PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.PRIMA-1Met可诱导华氏巨球蛋白血症细胞凋亡,且不依赖于p53。
Cancer Biol Ther. 2015;16(5):799-806. doi: 10.1080/15384047.2015.1026482.

本文引用的文献

1
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.瓦尔登斯特伦巨球蛋白血症患者 von Willebrand 因子水平低或高的临床和预后意义。
Blood. 2012 Oct 18;120(16):3214-21. doi: 10.1182/blood-2011-11-388256. Epub 2012 Aug 14.
2
MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts.华氏巨球蛋白血症肿瘤细胞中的 microRNA 表达反映了其正常细胞和恶性细胞对应物。
Blood Cancer J. 2011 Jun;1(6):e24. doi: 10.1038/bcj.2011.25. Epub 2011 Jun 17.
3
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.对边缘区和淋巴浆细胞淋巴瘤的基因组分析确定了常见和疾病特异性的异常。
Mod Pathol. 2012 May;25(5):651-60. doi: 10.1038/modpathol.2011.213. Epub 2012 Feb 3.
4
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.全面分析华氏巨球蛋白血症肿瘤微环境细胞因子,鉴定出 CCL5 是一种新型的 IL-6 活性调节剂。
Blood. 2011 Nov 17;118(20):5540-9. doi: 10.1182/blood-2011-04-351742. Epub 2011 Sep 14.
5
Intrinsic and extrinsic regulation of innate immune receptors.固有免疫受体的内在和外在调节。
Yonsei Med J. 2011 May;52(3):379-92. doi: 10.3349/ymj.2011.52.3.379.
6
Novel M-component based biomarkers in Waldenström's macroglobulinemia.基于新型 M 成分的华氏巨球蛋白血症生物标志物。
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):164-7. doi: 10.3816/CLML.2011.n.039.
7
Jak/Stat pathway in Waldenström's macroglobulinemia.Jak/Stat 通路在巨球蛋白血症中的作用。
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):112-4. doi: 10.3816/CLML.2011.n.023.
8
Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.双重PI3/Akt和mTOR抑制在华氏巨球蛋白血症中的作用。
Oncotarget. 2010 Nov;1(7):578-582. doi: 10.18632/oncotarget.192.
9
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.高磷酸化 paratarg-7:一种新的分子定义的 IgM 型意义未明的单克隆丙种球蛋白病和华氏巨球蛋白血症的风险因素。
Blood. 2011 Mar 10;117(10):2918-23. doi: 10.1182/blood-2010-09-306076. Epub 2011 Jan 10.
10
Oncogenically active MYD88 mutations in human lymphoma.人类淋巴瘤中致癌性激活的 MYD88 突变。
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.

华氏巨球蛋白血症的分子发病机制

Molecular pathogenesis of Waldenstrom's macroglobulinemia.

作者信息

Braggio Esteban, Philipsborn Casey, Novak Anne, Hodge Lucy, Ansell Stephen, Fonseca Rafael

机构信息

Department of Hematology-Oncology, Mayo Clinic in Arizona, 13400 East Shea Boulevard, Collaborative Research Building, Room 1-105, Scottsdale, AZ 85259-5494, USA.

出版信息

Haematologica. 2012 Sep;97(9):1281-90. doi: 10.3324/haematol.2012.068478. Epub 2012 Jul 6.

DOI:10.3324/haematol.2012.068478
PMID:22773606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3436227/
Abstract

Waldenström's macroglobulinemia is an indolent, lymphoproliferative disease, characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and high immunoglobulin M production. While technological advances over the past several decades have dramatically improved the possibilities of studying the molecular basis of Waldenström's macroglobulinemia, the pathogenesis of the disease remains fragmented. Undoubtedly, research has been successful in uncovering underlying aberrations and deregulated mechanisms in this disease, providing useful information for identifying biomarkers for disease diagnosis, risk stratification and therapeutic intervention, but there is still a long way to go before the pathogenesis of Waldenström's macroglobulinemia is fully revealed. In addition, the low number of in vitro or in vivo models significantly challenges extensive analysis. In this manuscript, we review the molecular basis of this disease.

摘要

华氏巨球蛋白血症是一种惰性淋巴细胞增殖性疾病,其特征为异质性淋巴浆细胞骨髓浸润和高免疫球蛋白M产生。尽管过去几十年的技术进步极大地改善了研究华氏巨球蛋白血症分子基础的可能性,但该疾病的发病机制仍然支离破碎。毫无疑问,研究已成功揭示了该疾病潜在的异常和失调机制,为识别疾病诊断、风险分层和治疗干预的生物标志物提供了有用信息,但在华氏巨球蛋白血症的发病机制完全揭示之前仍有很长的路要走。此外,体外或体内模型数量较少对广泛分析构成了重大挑战。在本手稿中,我们综述了该疾病的分子基础。